Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
about
Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complicationProtein carbonylation, cellular dysfunction, and disease progressionPyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H2O2-mediated cytotoxicity.3-hydroxypyridine chromophores are endogenous sensitizers of photooxidative stress in human skin cells.Emerging drugs for diabetic retinopathy.Pyridoxamine: the many virtues of a maillard reaction inhibitor.Vitamin B6: a long known compound of surprising complexity.Oxidative stress and the etiology of insulin resistance and type 2 diabetes.Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products.Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.Emerging drugs for diabetic nephropathy.The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes.Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker ratMetabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats.Pretreatment with pyridoxamine mitigates isolevuglandin-associated retinal effects in mice exposed to bright light.Acrolein scavengers: reactivity, mechanism and impact on health.Naturally occurring inhibitors against the formation of advanced glycation end-products.Therapeutic potential of targeting lipid aldehydes and lipoxidation end-products in the treatment of ocular disease.Prevention of protein glycation by natural compounds.Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes).Advanced glycation End-products (AGEs): an emerging concern for processed food industries.Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?Role of glucoxidation and lipid oxidation in the development of atherosclerosis.Reduction of methylglyoxal-induced glycation by pyridoxamine improves adipose tissue microvascular lesionsAerobic and resistance training do not influence plasma carnosinase content or activity in type 2 diabetes.The effect of B vitamin supplementation on wound healing in type 2 diabetic mice.Effects of methylglyoxal and pyridoxamine in rat brain mitochondria bioenergetics and oxidative status.The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes.Enzymic and non-enzymic cross-linking mechanisms in relation to turnover of collagen: relevance to aging and exercise.Lipid-derived modifications of plasma proteins in experimental and human diabetes.Renoprotective and lipid-lowering effects of LR compounds, novel advanced glycation end product inhibitors, in streptozotocin-induced diabetic rats.Pyridoxamine improves survival and limits cardiac dysfunction after MI.The effect of aminoguanidine (AG) and pyridoxamine (PM) on ageing human cortical bone.Serum Metabolomic Profiling of Sulphur Mustard-Exposed Individuals Using (1)H Nuclear Magnetic Resonance Spectroscopy.AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease.Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products.Substituting White Rice with Brown Rice for 16 Weeks Does Not Substantially Affect Metabolic Risk Factors in Middle-Aged Chinese Men and Women with Diabetes or a High Risk for DiabetesRole of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategiesReactive carbonyl species in vivo: generation and dual biological effects
P2860
Q26751110-56B7A166-C09D-4CBE-BA0F-B0DEE2CE95C1Q28248107-9904BBF6-598A-46A4-9FF3-F483359D8E50Q30358840-51F3BE7C-5663-4BD1-8436-4EA448CE13E3Q30831123-ABDDC5CB-E60B-465B-9C6B-00953B8EC3B3Q33388498-981ABC5C-7DFB-4A53-AD18-E8D213CE6D61Q34436025-D9C831F0-2A22-4448-9D27-A5E92BB341E4Q34603106-FEB006B1-FA1A-4007-9D8A-453DB0C388FBQ34768229-9A99A1A4-22B0-40CA-A914-396D4046EE5FQ34983879-F88522BB-4AE5-48BA-8387-A184B0E543C6Q36204031-8BF93AAA-27A8-49E2-A32B-2580999E7B87Q36204035-515D63EB-E864-426C-9570-A3787E42712CQ36302838-4DAFF825-A57C-4EA6-9D4E-346B50F5EE25Q36942530-D2DF0E22-B90E-4F67-BCDE-BA0E059A3F1BQ37029246-0141A690-97A4-421D-97A4-85AC5DDA0BA6Q37151490-8DDF26B1-2DC6-445B-9737-5CDC275EECECQ37226073-EB93D38D-3E92-4FD7-9B8B-F4E2F483E5B7Q37895630-1C458DA5-05AC-4DB0-9BD8-35C4B8B1C890Q37903708-80B7D55A-7227-4E88-BC7E-3912C4BC6C14Q38077549-07D50420-CC75-4362-BB45-AC2EFBA8556DQ38358965-0FD5F2F6-ABBC-4C7F-8E13-4BF2F611F12CQ38451830-4DF1DEFF-CA79-47E1-B83E-24753C0D89C9Q38647079-0ADD7CDD-51C8-43DB-81BB-5F38D5F73E62Q39158946-EC7E21EA-D82C-451C-A25A-21200684603DQ40394758-93B999ED-E651-4891-9851-C4FE4C592AC9Q40509761-5B794226-40EF-4E13-8CF9-53199C5F06DEQ40519605-3C471722-BF3D-4B91-B4AE-BDB8DF22781BQ41863810-E17E2560-754D-4D92-9ACB-0A80185CA4D9Q42705647-7F4D87E4-50D2-418A-87A8-B9D57E13B987Q45387265-D93F23F0-8CD0-494A-8631-3AB03D43D199Q46584500-121D327C-03F3-4CEF-9E7D-42E6A26A7C5AQ46613162-E9588314-1FE9-4062-B1F0-606A8203B6E2Q46613239-E0B08F25-08FD-4513-9DE0-DA69E3790476Q47426086-A793551A-4F1C-4C53-A276-E599353B3D91Q47549644-8D8FD250-ECC1-4F95-9C52-5CB6E0DD4C49Q48078306-456DB5D6-61D5-428F-88C5-0B0E158EE032Q51747235-5BD87D21-1EC2-4F87-9E3B-719BB9A6AA28Q53286585-6E4AF284-7780-4B19-8643-E693568DDD74Q58396601-6C23F901-3DC1-4267-8CE5-B8B4EF0FC30AQ58577346-CB7F4464-2E6C-49DF-AE14-D5D7A71F92AAQ59075718-4F01AAB0-8B9F-465E-ACAC-FCBA5A9BDEDA
P2860
Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pyridoxamine, an inhibitor of ...... ent of diabetic complications.
@ast
Pyridoxamine, an inhibitor of ...... ent of diabetic complications.
@en
type
label
Pyridoxamine, an inhibitor of ...... ent of diabetic complications.
@ast
Pyridoxamine, an inhibitor of ...... ent of diabetic complications.
@en
prefLabel
Pyridoxamine, an inhibitor of ...... ent of diabetic complications.
@ast
Pyridoxamine, an inhibitor of ...... ent of diabetic complications.
@en
P2093
P1476
Pyridoxamine, an inhibitor of ...... ent of diabetic complications.
@en
P2093
John W Baynes
Nathan L Alderson
Suzanne R Thorpe
P356
10.1016/J.ABB.2003.08.021
P407
P50
P577
2003-11-01T00:00:00Z